Core Viewpoint - RemeGen has entered a licensing agreement with AbbVie for RC148, which includes significant upfront and milestone payments, indicating strong market expectations for the drug's potential [1] Company Summary - RemeGen will receive an upfront payment of US$650 million and milestone payments of up to US$4.95 billion from AbbVie for the rights to develop, manufacture, and commercialize RC148 outside Greater China [1] - The licensing agreement is expected to alleviate RemeGen's cash position, which was RMB1.45 billion as of September 30, 2025 [2] Clinical Data Summary - RC148 demonstrated an overall response rate (ORR) of 61.9% and a disease control rate (DCR) of 100% in first-line PD-L1-positive NSCLC patients [2] - In combination with docetaxel for second/third-line NSCLC, RC148 showed an ORR of 66.7% and a median progression-free survival (mPFS) of 8.3 months [2] - The safety profile of RC148 is considered manageable, with clinical benefits observed across all subgroups [2] Industry Insights - The licensing-out activity in the China healthcare industry is expected to remain robust in 2026, particularly in the area of immuno-oncology (IO) [2] - The transaction reflects overseas recognition of RemeGen's R&D capabilities and highlights the competitive landscape of the PD-(L)1/VEGF market, with other companies like Pfizer also advancing their products [2]

Group 1: 康方生物 (Kangfang Biologics) - The report highlights the rapid advancement of the overseas registration and indication expansion for the drug依沃西 (Ivosidenib), with a positive outlook on its approval prospects [1] - The company has initiated multiple Phase III studies in mainland China this year, targeting large patient populations with limited treatment options, positioning依沃西 as a new generation I/O cornerstone drug [1] - The sales peak for依沃西 in China is adjusted to RMB 7.1 billion based on the point of sale (PoS) analysis [1] Group 2: 卡度尼利 (Cardunili) - 卡度尼利 has recently received approval for its third indication for first-line cervical cancer in the general population and is set to participate in the upcoming health insurance negotiations [2] - The company is initiating a Phase II study overseas for卡度尼利 in combination with lenvatinib, with potential registration and business development opportunities expected in the next 2-3 years [2] - The differentiated ADC development strategy is progressing well, with the first dual-antibody ADC AK146D1 completing its first patient enrollment [2] Group 3: 蔚来汽车 (NIO) - The pre-sale price of the NIO sub-brand's second model, 乐道 L90, exceeds expectations, starting at RMB 279,900, and can be as low as RMB 199,900 with battery-as-a-service (BaaS) [3] - The vehicle's pricing strategy positions it competitively against similar-sized models, offering superior space and performance, aiming to capture the family SUV market [3] - The report emphasizes the potential for a short-term rebound in stock price due to marginal improvements and a limited downside in the current market [6] Group 4: 房地产行业 (Real Estate Industry) - The overall real estate market remains stable during the peak season, with a 17.2% month-on-month increase in total sales in June 2025, reaching RMB 370.8 billion [7] - All top ten developers in June's sales ranking are state-owned enterprises, with Poly Developments leading the list [7] - The report anticipates further optimization of existing policies to promote real estate market development, with local governments expected to implement targeted measures [7][8]